Most people searching this topic ask, “How do I get a GLP-1 prescription?” The more useful question is, “How does a provider decide whether someone qualifies?”
Interest has never been higher. Gallup’s 2026 tracking found that 11% of U.S. adults currently take a GLP-1 for weight loss, up from 3% in 2024. Industry estimates also suggest that only about 1 in 10 clinically eligible people are being treated. Eligibility and access are clearly not the same thing.
Eligibility is a layered clinical judgment. It involves BMI and comorbidity thresholds, laboratory results, contraindications, and the source of the medication itself. The prescription is also not the end of the process; it is the beginning of a monitored program. This article explains how providers reason through these decisions. It is not a self-diagnosis tool, and it does not guarantee that any individual is a candidate.
The Starting Point: BMI and Comorbidity Thresholds Under Current Labeling
FDA labeling for approved GLP-1 weight-management medications sets the baseline framework clinicians use. The core threshold is:
- BMI of 30 kg/m² or greater (obesity), or
- BMI of 27 kg/m² or greater (overweight) with at least one weight-related comorbid condition, such as hypertension.
BMI is a screening threshold, not a standalone diagnosis. Providers interpret it alongside body composition, waist circumference, and the patient’s overall metabolic picture.
Labeling has also broadened. Expanded indications now include treatment of moderate to severe obstructive sleep apnea in adults with obesity and reduction of major adverse cardiovascular events in adults. As a result, eligibility conversations increasingly start from a health condition rather than a number on a scale.
How 2026 Guideline Updates Are Reshaping Who “Qualifies”
In March 2026, The Obesity Society, the Obesity Medicine Association, and the Obesity Action Coalition released a joint guideline. It expanded the suggested use cases for GLP-1 medications to include:
- Obstructive sleep apnea
- Heart failure with preserved ejection fraction (HFpEF)
- MASH and liver fat reduction
- Osteoarthritis
This shifts the central question from “What is the patient’s BMI?” to “What conditions are driving this patient’s risk?” For patients whose BMI sits near the threshold but who have significant comorbidities, providers now have more clinical grounds to consider treatment. Endocrinology guidance from AACE and ACE points the same way, increasingly anchoring obesity pharmacotherapy decisions to adiposity-based chronic disease staging rather than to BMI alone.
Before Any Prescription: The Labs a Provider Actually Orders
FDA prescribing information does not require specific labs before treatment begins. Responsible clinical practice fills that gap with a standard baseline workup:
- HbA1c
- Comprehensive metabolic panel, which covers kidney function (creatinine and eGFR), liver enzymes, and electrolytes
- Lipid panel
- Complete blood count (CBC)
- TSH
The 2026 ADA Standards of Care specifically recommend checking A1C, kidney function, and pregnancy status before starting any GLP-1 therapy. Each of these labs serves a clinical purpose:
- Kidney and liver function affect whether dosing is safe.
- Thyroid status helps rule out other causes of the patient’s symptoms.
- Baseline A1C and lipid values give a measurable reference point for tracking how the patient responds.
Monitoring Doesn’t Stop at the Starting Line
Labs are commonly repeated, with CMP and A1C often rechecked around 12 weeks. These follow-up tests track changes in kidney and liver function and in blood sugar control. Repeat labs are part of an ongoing clinical relationship, not a one-time gate, and this is the core difference between a prescription and a program.
Contraindications: What Absolutely Rules Someone Out vs. What Requires Judgment
Providers sort contraindications into two groups:
- Absolute contraindications are hard stops. If one is present, the medication is not prescribed.
- Relative contraindications call for an individualized weighing of risks and benefits.
In clinical practice, this distinction determines how “disqualification” actually works.
Absolute Contraindications (Label-Based, Non-Negotiable)
Labeling lists three absolute contraindications:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Serious hypersensitivity to the medication or its excipients
Labeling guidance also treats pregnancy as a contraindication. These are non-negotiable because they reflect documented, mechanism-specific risk rather than general caution.
Relative Contraindications (Where Clinical Judgment Comes In)
Providers weigh the following conditions case by case:
- History of pancreatitis
- Severe gastroparesis or other GI motility disorders
- Active gallbladder disease
- Diabetic retinopathy complications, particularly with certain high-dose regimens
- Active eating disorders
- Reduced kidney function
For each one, the clinician considers how severe the condition is, whether it is reversible, and whether it can be monitored safely during treatment. No blanket rule applies. This is where self-directed or minimally supervised access becomes risky. These decisions require a clinician who knows the patient’s full history, and a questionnaire cannot provide that.
Medication Source and Oversight: How the Prescribing Calculus Changes
The eligibility framework of thresholds, labs, and contraindications applies regardless of where the medication comes from. What changes is the oversight behind the medication itself, which affects what a provider can reasonably monitor.
A provider may discuss several medication options, including brand-name GLP-1s like Zepbound and compounded GLP-1s. At Red Mountain, these options are offered within the practice’s proprietary RM3® program, which pairs medication with the labs, coaching, and monitoring described throughout this article. Each medication option carries its own regulatory status, and a provider can walk through those details during an evaluation.
The 2026 Regulatory Shift That Changed Compounding Access
The regulatory landscape has changed in several steps:
- December 19, 2024: The FDA declared the tirzepatide shortage resolved.
- February 21, 2025: The FDA declared the semaglutide shortage resolved. Together, these decisions ended the shortage-based allowance for mass-scale compounding.
- April 30, 2026: The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list.
- August 27, 2026: The Fifth Circuit upheld the FDA’s shortage-resolution determinations.
In practical terms, compounding is now permitted only under narrower, patient-specific 503A circumstances. Broad, shortage-based compounding is no longer permitted.
What Minimal Oversight Actually Means for a Patient
When a compounded medication is obtained outside a structured evaluation, several safeguards are missing:
- There is no assurance of consistent dosing.
- There is no built-in lab screening.
- No clinician reviews contraindications in the context of the patient’s history.
In a provider-led process, a compounded medication is used only when clinically appropriate. It is paired with the same baseline labs, contraindication screening, and monitoring described above. A provider will explain the regulatory status of any medication before treatment begins.
Why the Prescription Marks the Start of a Program, Not the End of the Evaluation
Prescribing begins a series of ongoing clinical decisions. Dose titration is a core safety mechanism. GI side effects are closely tied to how quickly the dose is increased. A supervising clinician can hold a patient at a dose level longer or slow the escalation based on how well the patient tolerates it, rather than following a fixed schedule.
A 2025 joint advisory from the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society emphasized that nutritional and behavioral therapy should accompany GLP-1 treatment to help protect against muscle loss and nutrient deficiency. The advisory also noted that this kind of integration is “not widespread” in current practice.
At Red Mountain, medication is a tool within the Foundation stage of care. Labs, titration, nutrition coaching, and monitoring work together to support long-term metabolic health.
What This Means for Patients Wondering Whether They’d Qualify
During an evaluation, a provider works through four questions:
- Does the patient’s BMI and comorbidity profile meet labeled criteria or a guideline-supported expanded indication?
- Do the patient’s labs support starting treatment safely?
- Are there absolute or relative contraindications to weigh?
- What level of oversight will accompany the medication?
Borderline cases are common, such as a BMI near the threshold or a mild relative contraindication. These are exactly the cases where in-person clinical judgment matters most. A proper evaluation is the only reliable way to answer these questions.
Conclusion: Eligibility Is Determined, Not Assumed
A GLP-1 prescription reflects a provider’s clinical determination based on thresholds, labs, and contraindications. It is not the result of a transaction or a checklist. The quality of oversight behind a prescription, whether the medication is brand-name or compounded, shapes the safety and monitoring a patient can expect. Medication establishes a metabolic foundation; lasting results depend on the structure, monitoring, and support built around it.
Next Step: A Clinical Evaluation, Not a Guess
For anyone wondering whether they would qualify, a consult is usually the next reasonable step. Red Mountain’s in-person, clinically led evaluation includes a review of BMI and health history, baseline labs, and contraindication screening. The consult is designed for gathering information, not making a commitment, and it gives each patient a clear, individualized answer to the question this article has explored.
Red Mountain may prescribe a compounded version of a GLP-1. Compounded GLP-1s contain semaglutide or tirzepatide. Compounded GLP-1s have not been approved by the FDA or reviewed by the FDA for safety, effectiveness, or quality. Compounded GLP-1s have not been demonstrated to the FDA to be safe or effective for weight loss. Compounded GLP-1s manufacturing processes have not been reviewed by the FDA. FDA-approved products containing semaglutide and tirzepatide are available. Ask your provider for more information.